Molecular diagnostics company Diacarta Ltd. raised $45 million in its most recent series B funding and will apply the capital to expand its liquid biopsy cancer detection platform. The cash flow will be used toward Diacarta's XNA technology platform to detect cancer at an early stage and to expand globally. The round was led by Fortune Fountain Capital and included Good Health Capital. The company closed an $8 million series A funding in January 2015. Read More
